Patents by Inventor Steven Leventer

Steven Leventer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT USING AN MTORC1 MODULATOR
    Publication number: 20240041811
    Abstract: The present invention relates to methods, compositions, and unit dosage forms useful for selectively modulating mTORC1 activity.
    Type: Application
    Filed: June 29, 2023
    Publication date: February 8, 2024
    Inventors: Steven LEVENTER, Steven D. Targum
  • Methods of treatment using an mTORC1 modulator
    Patent number: 11723890
    Abstract: The present invention relates to methods, compositions, and unit dosage forms useful for selectively modulating mTORC1 activity.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: August 15, 2023
    Assignee: Navitor Pharmaceuticals, Inc.
    Inventors: Steven Leventer, Steven D. Targum
  • METHODS OF TREATMENT USING AN mTORC1 MODULATOR
    Publication number: 20210169835
    Abstract: The present invention relates to methods, compositions, and unit dosage forms useful for selectively modulating mTORC1 activity.
    Type: Application
    Filed: November 2, 2020
    Publication date: June 10, 2021
    Inventors: Steven LEVENTER, Steven D. TARGUM
  • Treatment of sexual dysfunction with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or salt thereof
    Publication number: 20070142395
    Abstract: Therapeutic methods are provided for treating sexual dysfunction by administration of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone, or a prodrug or salt thereof.
    Type: Application
    Filed: December 16, 2005
    Publication date: June 21, 2007
    Applicants: Vela Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd.
    Inventors: Steven Leventer, Robert Kucharik, Jeff Calcagno
  • Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
    Publication number: 20070032479
    Abstract: Compounds according to formula (I) wherein R1, R2, R3, R4, R5 and n are as defined herein, are administered at low dosage for the prevention or treatment of inflammatory disorders, particularly those affecting epithelial tissues such as those of the skin and gastrointestinal tract.
    Type: Application
    Filed: December 3, 2004
    Publication date: February 8, 2007
    Inventors: Steven Leventer, Robert Kucharik
  • Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S) 2,3-benzodiazepine
    Publication number: 20070021412
    Abstract: The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress that are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility, gastrointestinal inflammation, visceral hypersensitivity, or gastric ulcers.
    Type: Application
    Filed: June 21, 2006
    Publication date: January 25, 2007
    Applicant: Vela Pharmaceuticals, Inc.
    Inventors: Robert Kucharik, Steven Leventer
  • Compositions and methods for treating or preventing convulsions or seizures
    Publication number: 20060166976
    Abstract: The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefore. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially free of R-tofisopam with another anti-convulsant.
    Type: Application
    Filed: March 24, 2006
    Publication date: July 27, 2006
    Applicant: Vela Pharmaceuticals, Inc.
    Inventors: Steven Leventer, Robert Kucharik
  • Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S)-2,3-benzodiazepine
    Publication number: 20050288277
    Abstract: The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress which are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility, gastrointestinal inflammation, visceral hypersensitivity, or gastric ulcers.
    Type: Application
    Filed: June 25, 2004
    Publication date: December 29, 2005
    Inventors: Robert Kucharik, Steven Leventer
  • Compositions and methods for treating or preventing convulsions or seizures
    Publication number: 20050075329
    Abstract: The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefor. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially free of R-tofisopam with another anti-convulsant.
    Type: Application
    Filed: July 23, 2003
    Publication date: April 7, 2005
    Inventors: Steven Leventer, Robert Kucharik